PMC:7243768 / 5065-5272 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"194","span":{"begin":196,"end":204},"obj":"Species"},{"id":"197","span":{"begin":143,"end":162},"obj":"Chemical"}],"attributes":[{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"merica endowed a common statement on March 17 which mentioned that “since there is no scientific evidence behind ceasing the usage of ACEi and angiotensin type II receptor blockers (ARBs) for the patients af"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T63","span":{"begin":15,"end":16},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"merica endowed a common statement on March 17 which mentioned that “since there is no scientific evidence behind ceasing the usage of ACEi and angiotensin type II receptor blockers (ARBs) for the patients af"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T18","span":{"begin":134,"end":138},"obj":"Chemical"},{"id":"T19","span":{"begin":143,"end":154},"obj":"Chemical"},{"id":"T20","span":{"begin":160,"end":162},"obj":"Chemical"}],"attributes":[{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"merica endowed a common statement on March 17 which mentioned that “since there is no scientific evidence behind ceasing the usage of ACEi and angiotensin type II receptor blockers (ARBs) for the patients af"}